Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel(Duke University), Robert M. Califf(Duke University), Daniel E. Singer(Massachusetts General Hospital), Jonathan P. Piccini(Clinical Research Institute), Günter Breithardt(University Hospital Münster), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Keith A.A. Fox(University of Edinburgh), Guohua Pan(Johnson & Johnson (United States)), John F. Paolini(Synta Pharmaceuticals (United States)), Scott D. Berkowitz(Bayer (United States)), Christopher C. Nessel(Johnson & Johnson (United States)), Jyotsna Garg(Clinical Research Institute), Jonathan L. Halperin(Icahn School of Medicine at Mount Sinai), Richard C. Becker(University of Cincinnati), Werner Hacke(Heidelberg University), Graeme J. Hankey
Cited by 9,394
Related Papers
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k